Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Gulyamov was diagnosed with pre-eclampsia, a potentially dangerous complication that manifests as high blood pressure, protein in the woman’s urine, and often swelling that is indistinct from ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

With just a few weeks to go before the full announcement, many are revving their engines for full Nintendo Switch 2 pre-orders to open next month. That April 2 Direct date is approaching fast, and ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...

We read all day so you don't have to. Sign up for CNN Business' newsletter for the top stories you need to know.